SCM
CLRB icon

Sio Capital Management’s Cellectar Biosciences CLRB Stock Holding History

Sio Capital Management’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-7,294
Closed -$3.52M – 79
2021
Q1 		$3.52M Sell
7,294
-476
-6% -$283K 0.72% 46
2020
Q4 		$4.85M Buy
7,770
+3,222
+71% +$1.48M 0.99% 32
2020
Q3 		$1.69M Buy
4,548
+3,916
+620% +$1.55M 0.34% 65
2020
Q2 		$243K Buy
+632
New +$265K 0.07% 75

Other funds holding CLRB

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Sio Capital Management's CLRB Position: Q2 2021 in Review

Sio Capital Management sold out of Cellectar Biosciences (CLRB) in Q2 2021, closing a stake of 7,294 shares — an estimated $3.52M sold.

Sio Capital Management first reported a position in CLRB in Q2 2020 and held it in 4 quarters. The position peaked at $4.85M in Q4 2020. 43 funds tracked by Wall St. Rank hold CLRB as of Q2 2021.

  • Sio Capital Management reported no remaining Cellectar Biosciences position as of Q2 2021 after selling out during the quarter.
  • Sio Capital Management sold 7,294 Cellectar Biosciences shares in Q2 2021, an estimated $3.52M.
  • Sio Capital Management first reported a position in Cellectar Biosciences in Q2 2020 and held it in 4 quarters.
  • Sio Capital Management's Cellectar Biosciences position peaked at $4.85M in Q4 2020.
  • 43 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2021.

Based on Sio Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.